Neil Stahl - Dec 8, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Research and Development
Signature
/s/**Neil Stahl
Stock symbol
REGN
Transactions as of
Dec 8, 2023
Transactions value $
-$1,294,591
Form type
4
Date filed
12/12/2023, 04:05 PM
Previous filing
Nov 14, 2023
Next filing
Feb 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Tax liability -$683K -809 -1.54% $843.79 51.9K Dec 8, 2023 Direct
transaction REGN Common Stock Award $0 +853 +1.64% $0.00 52.7K Dec 8, 2023 Direct F1
transaction REGN Common Stock Tax liability -$612K -725 -1.37% $844.09 52K Dec 11, 2023 Direct
holding REGN Common Stock 5.83K Dec 8, 2023 By 401(k) Plan
holding REGN Common Stock 4.61K Dec 8, 2023 by Spouse as Trustee

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +3.06K $0.00 3.06K Dec 8, 2023 Common Stock 3.06K $843.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.